or the # 1 most important question...?
Why aren't we talking about the link between Covid and Endotoxemia in the media - thereby letting the investing public know about the potential key we hold to reducing Covid mortality. The PMX-HP device has been shown to remove endotoxins and it is accompanied by the only FDA approved companion diagnostic (the EAA). And it has had over 300,000 safe uses worldwide.
Is there any doubt that our CMO knows this?
listen from 19m mark for 3 min. to decide for yourself.
https://www.youtube.com/watch?v=GDu8P8_ntuA&t=6s
What about the general medical community's understanding?
Well here is just one example.
"Discussion/Conclusion:Elevated EA was observed in a large majority of critically ill patients with COVID-19 and multi-organ dysfunction despite a low incidence of concurrent gram-negative bacteremia. While we observed that elevated EA and nonresponsiveness to EA were associated with AKI in critically ill patients with COVID-19,..."
https://www.karger.com/Article/FullText/518230
So why aren't we talking? Possible answer to the question ?
"Well the is not sufficient scientific evidence yet. It requires more study !" To which I respond "Do all the other hundreds (thousands?) of Nasdaq traded biotech, drug, cancer research companies, etc. remain absolutely mum (silent) about
what they HOPE to be able to address/prove in the future via Pre-clinical trials, Phase 1 Trials, Phase 2 trials?, Phase 3 Trials? Or do they articulate what
might be possible once more data is avialable and they have gone through a formal FDA approval process?
And do they take every opportunity to tell their story, and attract investors in the meantime, in such a way that will help them to raise future dollars and be able to complete their Trials with a lower cost of capital, while at the same time enhancing shareholder value, thereby attracting more investment dollars, and minimize dilution, as they progress through the various research phases? "
MM